Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey
- PMID: 38633718
- PMCID: PMC10985827
- DOI: 10.36519/idcm.2022.163
Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey
Abstract
Objective: Urinary tract infections are one of the most common causes of morbidity around the world. Fosfomycin is a specific broad-spectrum antibiotic used to treat these infections. However, in recent years, many studies have reported increased fosfomycin resistance in Enterobacterales isolates. Therefore, this study aimed to evaluate the distribution of pathogens isolated from urine samples and find the fosfomycin resistance rates over nine years (2012-2020).
Materials and methods: A total of 18,884 uropathogenic Enterobacterales isolates were included in the study between 2012 and 2020. The isolates were identified by VITEK® 2 Compact (bioMérieux, Marcy l'Etoile, France), and the antimicrobial susceptibilities of the isolates were also evaluated using the VITEK® MS automated system (bioMérieux, Marcy l'Etoile, France).
Results: Escherichia coli (64.04%) was the most common bacteria among Enterobacterales. Fosfomycin resistance rates were 1.98%, 21.64%, and 10.36% in E. coli, Klebsiella pneumoniae, and all bacteria, respectively. The 34.97% of isolates were extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, and the fosfomycin resistance rate was 13.08% in these isolates. In addition, fosfomycin resistance rates were found as 3.06% and 23.84% in ESBL-producing E. coli and ESBL-producing K. pneumoniae, respectively.
Conclusion: Fosfomycin seems a good option for effectively treating UTIs caused by E. coli. On the other hand, we found that fosfomycin resistance tends to increase over the years. Therefore, we recommend further studies to evaluate fosfomycin resistance.
Keywords: Enterobacterales; extended-spectrum beta-lactamases producing; fosfomycin resistance.
Copyright © 2024 Infectious Diseases and Clinical Microbiology.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31. Int Urol Nephrol. 2015. PMID: 26026972
-
Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.J Microbiol Immunol Infect. 2011 Oct;44(5):364-8. doi: 10.1016/j.jmii.2010.08.012. Epub 2011 Jan 20. J Microbiol Immunol Infect. 2011. PMID: 21524974
-
Sickle cell disease children's gut colonization by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales: an antibiotic prophylaxis effect?J Med Microbiol. 2021 Sep;70(9). doi: 10.1099/jmm.0.001414. J Med Microbiol. 2021. PMID: 34477545
-
Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. doi: 10.1111/j.1469-0691.2007.01852.x. Clin Microbiol Infect. 2008. PMID: 18154548 Review.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
Cited by
-
Fosfomycin resistance in extended-spectrum beta-lactamase producing Escherichia coli isolated from urinary tract-infected patients in a tertiary care hospital.J Med Microbiol. 2025 Jul;74(7):002039. doi: 10.1099/jmm.0.002039. J Med Microbiol. 2025. PMID: 40658603 Free PMC article.
-
A Retrospective Analysis of Urinary Tract Infections With Special Reference to the Phenotypic and Genotypic Detection of Fosfomycin-Resistant Escherichia coli Isolates at a Tertiary Care Center in South India.Cureus. 2025 Jul 5;17(7):e87359. doi: 10.7759/cureus.87359. eCollection 2025 Jul. Cureus. 2025. PMID: 40765608 Free PMC article.
-
Comprehensive analysis of antibiotic resistance in Enterobacteriaceae from outpatient urine cultures: Implications for empirical therapy.North Clin Istanb. 2025 Jan 31;12(1):36-44. doi: 10.14744/nci.2024.25564. eCollection 2025. North Clin Istanb. 2025. PMID: 40838234 Free PMC article.
References
-
- Kahlmeter G. The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother. 2000;46(Suppl A):15–22. - PubMed
LinkOut - more resources
Full Text Sources